Comparison
CJC-1295 vs. DSIP
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Research other
CAS no.
no data
62568-57-4
Molecular weight
3647.3 g/mol
848.81 g/mol
Half-life
144 h
0.1 h
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACTrp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluMechanism of action
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Evidence base
Highest evidence
Human trial
Human trial
Studies
3
4
of which in humans
2
1
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
3
1